

# John D Fraser

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7319206/publications.pdf>

Version: 2024-02-01

50  
papers

3,038  
citations

186209

28  
h-index

206029

48  
g-index

51  
all docs

51  
docs citations

51  
times ranked

2651  
citing authors

#	ARTICLE	IF	CITATIONS
1	The economic and health burdens of diseases caused by group A Streptococcus in New Zealand. <i>International Journal of Infectious Diseases</i> , 2021, 103, 176-181.	1.5	18
2	Uncoupling Molecular Testing for SARS-CoV-2 From International Supply Chains. <i>Frontiers in Public Health</i> , 2021, 9, 808751.	1.3	2
3	The global response to the COVID-19 pandemic: how have immunology societies contributed?. <i>Nature Reviews Immunology</i> , 2020, 20, 594-602.	10.6	17
4	Impact of Superantigen-Producing Bacteria on T Cells from Tonsillar Hyperplasia. <i>Pathogens</i> , 2019, 8, 90.	1.2	9
5	Atlas of group A streptococcal vaccine candidates compiled using large-scale comparative genomics. <i>Nature Genetics</i> , 2019, 51, 1035-1043.	9.4	120
6	Enterotoxins can support CAR T cells against solid tumors. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 25229-25235.	3.3	16
7	An economic case for a vaccine to prevent group A streptococcus skin infections. <i>Vaccine</i> , 2018, 36, 6968-6978.	1.7	41
8	Therapeutic potential of staphylococcal superantigen-like protein 7 for complement-mediated hemolysis. <i>Journal of Molecular Medicine</i> , 2018, 96, 965-974.	1.7	5
9	Development of an opsonophagocytic killing assay for group a streptococcus. <i>Vaccine</i> , 2018, 36, 3756-3763.	1.7	23
10	A potential role for staphylococcal and streptococcal superantigens in driving skewing of TCR V $\beta$ 2 subsets in tonsillar hyperplasia. <i>Medical Microbiology and Immunology</i> , 2017, 206, 337-346.	2.6	9
11	Clinical development strategy for a candidate group A streptococcal vaccine. <i>Vaccine</i> , 2017, 35, 2007-2014.	1.7	18
12	Staphylococcal enterotoxin-like X (SEIX) is a unique superantigen with functional features of two major families of staphylococcal virulence factors. <i>PLoS Pathogens</i> , 2017, 13, e1006549.	2.1	32
13	Status of research and development of vaccines for <i>Streptococcus pyogenes</i> . <i>Vaccine</i> , 2016, 34, 2953-2958.	1.7	113
14	Comparative M-protein analysis of <i>Streptococcus pyogenes</i> from pharyngitis and skin infections in New Zealand: Implications for vaccine development. <i>BMC Infectious Diseases</i> , 2016, 16, 561.	1.3	25
15	M-Protein Analysis of <i>Streptococcus pyogenes</i> Isolates Associated with Acute Rheumatic Fever in New Zealand. <i>Journal of Clinical Microbiology</i> , 2015, 53, 3618-3620.	1.8	43
16	Iridium-Catalysed C $\alpha$ -H Borylation Facilitates a Total Synthesis of the HRV 3C Protease Inhibitor (A $\pm$ )-Thysanone. <i>Synlett</i> , 2014, 25, 556-558.	1.0	7
17	Streptococcal superantigens: categorization and clinical associations. <i>Trends in Molecular Medicine</i> , 2014, 20, 48-62.	3.5	97
18	High Usage of Topical Fusidic Acid and Rapid Clonal Expansion of Fusidic Acid-Resistant <i>Staphylococcus aureus</i> : A Cautionary Tale. <i>Clinical Infectious Diseases</i> , 2014, 59, 1451-1454.	2.9	64

#	ARTICLE	IF	CITATIONS
19	Working towards a Group A Streptococcal vaccine: Report of a collaborative Trans-Tasman workshop. <i>Vaccine</i> , 2014, 32, 3713-3720.	1.7	44
20	Synthesis and Biological Evaluation of 7-Deoxy Analogues of the Human Rhinovirus 3C Protease Inhibitor Thysanone. <i>European Journal of Organic Chemistry</i> , 2014, 2014, 122-128.	1.2	9
21	An Engineered Non-Toxic Superantigen Increases Cross Presentation of Hepatitis B Virus Nucleocapsids by Human Dendritic Cells. <i>PLoS ONE</i> , 2014, 9, e93598.	1.1	12
22	Full functional activity of SSL7 requires binding of both complement C5 and IgA. <i>Immunology and Cell Biology</i> , 2013, 91, 469-476.	1.0	24
23	A modified superantigen rescues Ly6G <sup>+</sup> CD11b <sup>+</sup> blood monocyte suppressor function and suppresses antigen-specific inflammation in EAE. <i>Autoimmunity</i> , 2013, 46, 269-278.	1.2	5
24	Characterization of a Mouse-Adapted <i>Staphylococcus aureus</i> Strain. <i>PLoS ONE</i> , 2013, 8, e71142.	1.1	58
25	Antigen Targeting to Major Histocompatibility Complex Class II with Streptococcal Mitogenic Exotoxin Z-2 M1, a Superantigen-Based Vaccine Carrier. <i>Vaccine Journal</i> , 2012, 19, 574-586.	3.2	6
26	Structural and Functional Properties of Staphylococcal Superantigen-Like Protein 4. <i>Infection and Immunity</i> , 2012, 80, 4004-4013.	1.0	33
27	Synthesis and anti- <i>Helicobacter pylori</i> activity of analogues of spiroloxine methyl ether. <i>MedChemComm</i> , 2012, 3, 938.	3.5	10
28	<i>Staphylococcus aureus</i> regulates the expression and production of the staphylococcal superantigen-like secreted proteins in a RotA-dependent manner. <i>Molecular Microbiology</i> , 2011, 81, 659-675.	1.2	53
29	Clarifying the Mechanism of Superantigen Toxicity. <i>PLoS Biology</i> , 2011, 9, e1001145.	2.6	42
30	Specificity of Staphylococcal Superantigen-Like Protein 10 toward the Human IgG1 Fc Domain. <i>Journal of Immunology</i> , 2010, 184, 6283-6292.	0.4	65
31	Staphylococcal Superantigen Super-Domains in Immune Evasion. <i>Critical Reviews in Immunology</i> , 2010, 30, 149-165.	1.0	38
32	Targeting Antigen to MHC Class II Molecules Promotes Efficient Cross-Presentation and Enhances Immunotherapy. <i>Journal of Immunology</i> , 2009, 182, 1260-1269.	0.4	37
33	The crystal structure of staphylococcal superantigen-like protein 11 in complex with sialyl Lewis X reveals the mechanism for cell binding and immune inhibition. <i>Molecular Microbiology</i> , 2008, 67, 473-473.	1.2	0
34	The bacterial superantigen and superantigen-like proteins. <i>Immunological Reviews</i> , 2008, 225, 226-243.	2.8	415
35	Crystal Structures of the Staphylococcal Toxin SSL5 in Complex with Sialyl Lewis X Reveal a Conserved Binding Site that Shares Common Features with Viral and Bacterial Sialic Acid Binding Proteins. <i>Journal of Molecular Biology</i> , 2007, 374, 1298-1308.	2.0	62
36	The crystal structure of staphylococcal superantigen-like protein 11 in complex with sialyl Lewis X reveals the mechanism for cell binding and immune inhibition. <i>Molecular Microbiology</i> , 2007, 66, 1342-1355.	1.2	85

#	ARTICLE	IF	CITATIONS
37	The Staphylococcal Superantigen-Like Protein 7 Binds IgA and Complement C5 and Inhibits IgA-FcγRI Binding and Serum Killing of Bacteria. <i>Journal of Immunology</i> , 2005, 174, 2926-2933.	0.4	237
38	Bacterial superantigens and immune evasion. , 2003, , 171-200.		1
39	The Three-dimensional Structure of a Superantigen-like Protein, SET3, from a Pathogenicity Island of the <i>Staphylococcus aureus</i> Genome. <i>Journal of Biological Chemistry</i> , 2002, 277, 32274-32281.	1.6	77
40	Superantigens – powerful modifiers of the immune system. <i>Trends in Molecular Medicine</i> , 2000, 6, 125-132.	2.6	147
41	The Streptococcal Superantigen Smez Exhibits Wide Allelic Variation, Mosaic Structure, and Significant Antigenic Variation. <i>Journal of Experimental Medicine</i> , 2000, 191, 1765-1776.	4.2	78
42	Superantigens in human disease. <i>Journal of Clinical Immunology</i> , 1999, 19, 149-157.	2.0	43
43	Superantigens: Just Like Peptides Only Different. <i>Journal of Experimental Medicine</i> , 1998, 187, 819-821.	4.2	39
44	The Superantigen Streptococcal Pyrogenic Exotoxin C (SPE-C) Exhibits a Novel Mode of Action. <i>Journal of Experimental Medicine</i> , 1997, 186, 375-383.	4.2	76
45	Crystal structure of the streptococcal superantigen SPE-C: dimerization and zinc binding suggest a novel mode of interaction with MHC class II molecules. <i>Nature Structural Biology</i> , 1997, 4, 635-643.	9.7	104
46	T-Cell Receptor beta-Chain Binding to Enterotoxin Superantigens. <i>Immunological Reviews</i> , 1993, 131, 61-78.	2.8	41
47	Enterotoxin residues determining T-cell receptor Vβ2 binding specificity. <i>Nature</i> , 1992, 359, 841-843.	13.7	87
48	Superantigen data. <i>Nature</i> , 1992, 360, 423-423.	13.7	4
49	High-affinity binding of staphylococcal enterotoxins A and B to HLA-DR. <i>Nature</i> , 1989, 339, 221-223.	13.7	428
50	The Streptococcal Superantigens. , 0, , 1-20.		0